Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen.
The aim of this study was to determine the compliance rates for women being offered routine antenatal anti-D prophylaxis in two obstetric units in the UK. Haemolytic disease of the newborn (HDN) is a potentially serious condition that can result in substantial morbidity and sometimes death. Current guidelines recommend that 500 IU anti-D immunoglobulin G (IgG) should be offered to all non-sensitized RhD-negative women at 28 and 34 weeks' gestation in order to prevent the risk of RhD sensitization in pregnancy. Implementing guidance, however, remains a challenge. We conducted a retrospective audit of 207 RhD-negative, non-sensitized pregnant women attending obstetric units during 2004 to assess compliance with national guidance on the provision of antenatal anti-D prophylaxis. Informed consent for routine antenatal anti-D prophylaxis was documented for 185 of these women. In total, 86.5% of women received the two doses of anti-D IgG. The majority of women received their first and second doses within 1 week of 28 and 34 weeks' gestation (87.0 and 86.0%, respectively). Accurate records of prophylactic anti-D IgG were maintained and updated. This audit demonstrates that the level of patient compliance with the two-dose regimen was high.
Chaffe
B
B
Blood Transfusion Department, William Harvey Hospital, Ashford, Kent, UK. bill.chaffe@ekht.nhs.uk
Ford
J
J
Bills
V
V
D004334:Drug Administration Schedule; D004899:Erythroblastosis, Fetal / Q000517:prevention & control; D005260:Female; D006801:Humans; D008485:Medical Audit; D010349:Patient Compliance; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D011263:Pregnancy Trimester, Third; D011295:Prenatal Care / Q000379:methods*; D012189:Retrospective Studies; D012203:Rh Isoimmunization / Q000517:prevention & control*; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage*
D018029:Rho(D) Immune Globulin